Patents for second medical use have been granted by the EPO for a long time but experiences show that the regulatory system on generic substitution has a great impact on if, how and against who such patents can be enforced. After a brief outlook on recent developments in other EU countries there will be a focus on a comparative study of problems and possible solutions in Denmark, Norway and Sweden.
Panel Speakers: Attorney at Law Sture Rygaard, Plesner, Attorney at Law Amund Brede Svendsen, Grette and Attorney at Law Jonas Westerberg, Lindahl
Moderator: Attorney at law Håkan Borgenhäll, Vinge
